Skip to main content

Grafa News and Videos — Page 1080

Grafa Headlines

Latest

Grafa

PureTech's Seaport advancing anxiety drug to Phase 2 on positive trial data

PureTech Health reported that its founded entity, Seaport Therapeutics (NASDAQ:SPTX), achieved positive clinical results from the multiple-ascending dose portion of its Phase 1 proof-of-concept trial evaluating its lead anti-anxiety candidate, GlyphAgo.

Read more: PureTech's Seaport advancing anxiety drug to Phase 2 on positive trial data

GET YOUR GRAFA EDGE NOW

We'll switch on a 30-day Edge trial as a welcome gift